Richard Lerner & Gregory Winter

2012 Prince of Asturias Award for TECHNICAL & SCIENTIFIC RESEARCH

Richard Lerner & Gregory Winter

The researchers Gregory Winter and Richard A. Lerner stand at the forefront of research on the immune system. The advances in the use of antibodies as therapeutic tools have provided new ways of preventing and treating immune disorders, degenerative diseases and different types of tumours. In many cases, the use of antibodies has alleviated the suffering of patients and has halted the progression of the disease.

These researchers have managed to create a synthetic immune system in the test tube, as well as demonstrating its preventive and therapeutic potential due to exceeding the natural antibody repertoire the human body can generate.

Gregory Winter Biography

Sir Gregory Winter (UK, 1951) studied Natural Sciences at Trinity College, Cambridge and undertook his PhD studies at the Laboratory of Molecular Biology (LMB) at the Medical Research Council (MRC), an institution of which he has been deputy director. He is Master of Trinity College.

Commander of the British Empire and a Fellow of The Royal Society, the Academy of Medical Sciences of the United Kingdom, the Australian Academy of Technological Sciences and Engineering and the Swedish Academy of Engineering Science.

Gregory Winter Awards

  • The Louis Jeantet Prize for Medicine (Switzerland, 1989)
  • The Emil von Behring Prize (Germany, 1990)
  • The Milan Award (Italy, 1990)
  • The Scheele Award of the Swedish Academy of Pharmaceutical Sciences (1994)
  • The King Faisal International Prize in Medicine (Saudi Arabia, 1995)
  • The Biochemical Society Award (UK, 2006)
  • The BioIndustry Association Award (UK, 2008)
  • The Prince of Asturias Award for Technical & Scientific Research (Spain, 2012)

Gregory Winter Research

Within the LMB, Winter has been one of the leading biochemists in innovative techniques for creating monoclonal therapeutic antibodies and one of the pioneers in the development of techniques for the humanization of these antibodies, a key step for the human immune system not to identify them as foreign agents. He holds numerous patents and, in addition to being scientific advisor to several genetic engineering firms, was the founder in 1989 of Cambridge Antibody Technology, a biotechnology company promoted by the LMB to market these antibodies, including adalimumab for treating rheumatoid arthritis and Crohn's disease. He also founded the companies Domantis in 2000 and Bicycle Therapeutics in 2009.

Richard Lerner Biography

Richard Alan Lerner (Chicago, USA, 1938) studied medicine at Northwestern University and Stanford, earning his PhD at the latter in 1964. Following internship at the Palo Alto Stanford Hospital in 1965, he began his career in research and teaching in the Department of Experimental Pathology at the Scripps Research Institute in La Jolla (California), an institution of which he was president from 1991 to 2012.

He is currently the Lita Annenberg Hazen Professor of Immunochemistry in the Department of Molecular Biology at Scripps and a member of the Skaggs Institute for Chemical Biology.

Richard Lerner Awards

  • Honorary degrees from seven universities in Europe and America
  • The Wolf Prize in Chemistry (Israel, 1995)
  • The William B. Coley Award from the Cancer Research Institute (USA, 1999)
  • The Paul Ehrlich and Ludwig Darmstaedter Prize (Germany, 2003).
  • The Prince of Asturias Award for Technical & Scientific Research (Spain, 2012)

Richard Lerner Research

Lerner was the architect of the most important advance since the discovery of monoclonal antibodies a quarter century ago: the conception, design and creation of combinatorial antibody libraries, currently the most widely used of all libraries in the field of biochemistry and which enabled a broadening of the scope of action of the immune system.

Lerner set the stage in an article published in Science in 1989 and all the advances produced in the change in combinatorial libraries derived directly or indirectly from this article. Furthermore, in 1991, Lerner identified the essence of the production of antibodies without immunization and his method has remained the most efficient way to produce fully human antibodies.

Moreover, Lerner has been a pioneer in the development of what are known as catalytic antibodies, a strategy to accelerate and catalyse chemical reactions for which traditional methods are not efficient.

Minutes of the jury

At its meeting held in Oviedo, the Jury for the 2012 Prince of Asturias Award for Technical and Scientific Research, composed of Mr Juan Luis Arsuaga Ferreras, Mr Juan Ignacio Cirac Sasturáin, Mr Antonio Fernández-Rañada Menéndez de Luarca, Mr Luis Fernández-Vega Sanz, Ms Cristina Garmendia Mendizábal, Mr Santiago Grisolía García, Ms María del Rosario Heras Celemín, Mr Bernardo Hernández González, Mr Emilio Lora-Tamayo D'Ocón, Mr José Antonio Martínez álvarez, Ms Petra Mateos-Aparicio Morales, Mr Amador Menéndez Velázquez, Mr Ginés Morata Pérez, Mr Enrique Moreno González, Mr César Nombela Cano, Mr Eduardo Punset Casals, Ms Marta Sanz-Solé, Mr Manuel Toharia Cortés, chaired by Mr Pedro Miguel Echenique Landiríbar and with Mr Vicente Gotor Santamaría acting as secretary, has unanimously decided to bestow the 2012 Prince of Asturias Award for Technical and Scientific Research on the British biologist Gregory Winter and the US pathologist Richard A. Lerner for their decisive contributions to the field of immunology and, in particular, for obtaining antibodies of major therapeutic value.

Antibodies are an essential part of the immune system with an enormous ability to recognize what is a constitutive element of the organism and to defend it especially against foreign bodies. Winter has discovered the way to modify antibody-producing animal cells so that these can function in the human organism without being rejected. Lerner's creation of combinatorial libraries of antibodies enables the construction of immunological repertoires far superior to those produced by the human immune system. As a result of their research, it is now possible to treat degenerative diseases and tumours with specifically designed antibodies, opening up new avenues for personalized medicine, preventive medicine and other applications such as chemical catalysis.

Oviedo, 31st May 2012